Table of Contents
Thrombosis
Volume 2012 (2012), Article ID 108983, 10 pages
http://dx.doi.org/10.1155/2012/108983
Review Article

Stroke Prevention in Atrial Fibrillation: Understanding the New Oral Anticoagulants Dabigatran, Rivaroxaban, and Apixaban

1Department of Cardiology, National Heart Centre Singapore, 17 Third Hospital Avenue, Singapore 168752
2Duke-NUS Graduate Medical School, 8 College Road, Singapore 169857
3Department of Cardiology, National University Heart Centre, 5 Lower Kent Ridge Road, Singapore 119074
4Mount Elizabeth Medical Centre, 3 Mount Elizabeth No. 14-10, Singapore 228510
5Mount Elizabeth Medical Centre, 3 Mount Elizabeth No. 14-01, Singapore 228510
6Gleneagles Medical Centre, 6 Napier Road No. 03-04, 25499, Singapore
7Department of Neurology, National Neuroscience Institute, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore 308433

Received 29 June 2012; Accepted 1 August 2012

Academic Editor: Walter Ageno

Copyright © 2012 Tan Ru San et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. G. Hart, L. A. Pearce, and M. I. Aguilar, “Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation,” Annals of Internal Medicine, vol. 146, no. 12, pp. 857–867, 2007. View at Google Scholar · View at Scopus
  2. E. M. Hylek, A. S. Go, Y. Chang et al., “Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation,” The New England Journal of Medicine, vol. 349, no. 11, pp. 1019–1026, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Ansell, J. Hirsh, E. Hylek, A. Jacobson, M. Crowther, and G. Palareti, “Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition),” Chest, vol. 133, supplement 6, pp. 160S–198S, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Sato, K. Ishikawa, A. Kitabatake et al., “Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan atrial fibrillation stroke trial,” Stroke, vol. 37, no. 2, pp. 447–451, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Mant, F. R. Hobbs, K. Fletcher et al., “Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial,” The Lancet, vol. 370, no. 9586, pp. 493–503, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. S. J. Connolly, J. Pogue, R. G. Hart et al., “Effect of clopidogrel added to aspirin in patients with atrial fibrillation,” The New England Journal of Medicine, vol. 360, no. 20, pp. 2066–2078, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Connolly, J. Pogue, R. Hart et al., “Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial,” The Lancet, vol. 367, no. 9526, pp. 1903–1912, 2006. View at Google Scholar
  8. S. B. Olsson, “Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial,” The Lancet, vol. 362, no. 9397, pp. 1691–1698, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. G. W. Albers, H. C. Diener, L. Frison et al., “Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial,” JAMA, vol. 293, no. 6, pp. 690–698, 2005. View at Google Scholar
  10. H. C. Diener, “Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation: pooled analysis from the SPORTIF III and V studies,” Cerebrovascular Diseases, vol. 21, no. 4, pp. 279–293, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. W. M. Lee, D. Larrey, R. Olsson et al., “Hepatic findings in long-term clinical trials of ximelagatran,” Drug Safety, vol. 28, no. 4, pp. 351–370, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Brinker, R. He, M. Desai, K. Gelperin, K. Robie-Suh, and V. Gurewich, “Safety of ximelagatran,” Journal of the American Medical Association, vol. 293, no. 23, pp. 2859–2860, 2005. View at Google Scholar · View at Scopus
  13. S. J. Connolly, M. D. Ezekowitz, S. Yusuf et al., “Dabigatran versus warfarin in patients with atrial fibrillation,” The New England Journal of Medicine, vol. 361, no. 12, pp. 1139–1151, 2009. View at Google Scholar
  14. M. R. Patel, K. W. Mahaffey, J. Garg et al., “Rivaroxaban versus warfarin in nonvalvular atrial fibrillation,” The New England Journal of Medicine, vol. 365, no. 10, pp. 883–891, 2011. View at Google Scholar
  15. C. B. Granger, J. H. Alexander, J. J. McMurray et al., “Apixaban versus warfarin in patients with atrial fibrillation,” The New England Journal of Medicine, vol. 365, no. 11, pp. 981–992, 2011. View at Google Scholar
  16. S. J. Connolly, J. Eikelboom, C. Joyner et al., “Apixaban in patients with atrial fibrillation,” The New England Journal of Medicine, vol. 364, no. 9, pp. 806–817, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. J. L. Mega, “A new era for anticoagulation in atrial fibrillation,” The New England Journal of Medicine, vol. 365, no. 11, pp. 1052–1054, 2011. View at Google Scholar
  18. Pradaxa (Dabigatran Etexilate Mesylate) Product Information, Boehringer Ingelheim Pharmaceuticals, Ridgefield, DC, USA, 2011.
  19. Xarelto (Rivaroxaban). Product Information, Bayer Pharma AG, Berlin, Germany, 2011.
  20. Eliquis (Apixaban) Product Information, Bristol-Myers Squibb/Pfizer EEIG, Uxbridge, UK, 2011.
  21. S. J. Connolly, M. D. Ezekowitz, S. Yusuf, P. A. Reilly, and L. Wallentin, “Newly identified events in the RE-LY trial,” The New England Journal of Medicine, vol. 363, no. 19, pp. 1875–1876, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Stangier, “Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate,” Clinical Pharmacokinetics, vol. 47, no. 5, pp. 285–295, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Kubitza, M. Becka, B. Voith, M. Zuehlsdorf, and G. Wensing, “Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor,” Clinical Pharmacology and Therapeutics, vol. 78, no. 4, pp. 412–421, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. N. Raghavan, C. E. Frost, Z. Yu et al., “Apixaban metabolism and pharmacokinetics after oral administration to humans,” Drug Metabolism and Disposition, vol. 37, no. 1, pp. 74–81, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. P. C. Wong, E. J. Crain, B. Xin et al., “Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies,” Journal of Thrombosis and Haemostasis, vol. 6, no. 5, pp. 820–829, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. W. Wienen, J. M. Stassen, H. Priepke, U. J. Ries, and N. Hauel, “In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate,” Thrombosis and Haemostasis, vol. 98, no. 1, pp. 155–162, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. A. G. G. Turpie, “Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 6, pp. 1238–1247, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. E. T. Yin and S. Wessler, “Investigation of the apparent thrombogenicity of thrombin,” Thrombosis et Diathesis Haemorrhagica, vol. 20, no. 3, pp. 465–468, 1968. View at Google Scholar · View at Scopus
  29. J. Van Ryn, J. Stangier, S. Haertter et al., “Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity,” Thrombosis and Haemostasis, vol. 103, no. 6, pp. 1116–1127, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. M. M. Samama, J. L. Martinoli, L. LeFlem et al., “Assessment of laboratory assays to measure rivaroxaban—an oral, direct factor Xa inhibitor,” Thrombosis and Haemostasis, vol. 103, no. 4, pp. 815–825, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. C. Barrett, Z. Wang, C. Frost, and A. Shenker, “Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay,” Thrombosis and Haemostasis, vol. 104, no. 6, pp. 1263–1271, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. K. H. Liesenfeld, T. Lehr, C. Dansirikul et al., “Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial,” Journal of Thrombosis and Haemostasis, vol. 9, no. 11, pp. 2168–2175, 2011. View at Google Scholar
  33. B. I. Eriksson, L. C. Borris, O. E. Dahl et al., “A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement,” Circulation, vol. 114, no. 22, pp. 2374–2381, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Graff, N. Von Hentig, F. Misselwitz et al., “Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity,” Journal of Clinical Pharmacology, vol. 47, no. 11, pp. 1398–1407, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. S. V. Ambudkar, C. Kimchi-Sarfaty, Z. E. Sauna, and M. M. Gottesman, “P-glycoprotein: from genomics to mechanism,” Oncogene, vol. 22, no. 47, pp. 7468–7485, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. F. Wagner, H. Peters, S. Formella et al., “Effective elimination of dabigatran with haemodialysis: a phase I single centre study in patients with end-stage renal disease,” Circulation, vol. 124, Abstract A13303, no. 21, 2011. View at Google Scholar
  37. J. van Ryn, T. Litzenburger, A. Waterman et al., “Dabigatran anticoagulant activity is neutralized by an antibody selective to dabigatran in in vitro and in vivo models,” Journal of the American College of Cardiology, vol. 57, no. 14, 2011. View at Google Scholar
  38. G. Lu, F. R. Deguzman, M. J. Karbarz et al., “Reversal of rivaroxaban mediated anticoagulation in animal models by a recombinant antidote protein (r-Antidote, PRT064445),” European Heart Journal, vol. 32, pp. 640–641, 2011. View at Google Scholar
  39. S. Ghanny, T. E. Warkentin, and M. A. Crowther, “Reversing anticoagulant therapy,” Current Drug Discovery Technologies, vol. 9, no. 2, pp. 143–149, 2012. View at Google Scholar
  40. E. S. Eerenberg, P. W. Kamphuisen, M. K. Sijpkens et al., “Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects,” Circulation, vol. 124, no. 14, pp. 1573–1579, 2011. View at Google Scholar
  41. A. Godier, A. Miclot, B. Le Bonniec et al., “Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model,” Anesthesiology, vol. 116, no. 1, pp. 94–102, 2012. View at Google Scholar
  42. W. Zhou, S. Schwarting, S. Illanes et al., “Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran,” Stroke, vol. 42, no. 12, pp. 3594–3599, 2011. View at Google Scholar
  43. J. Beyer-Westendorf and H. Buller, “External and internal validity of open label or double-blind trials in oral anticoagulation: better, worse or just different?” Journal of Thrombosis and Haemostasis, vol. 9, no. 11, pp. 2153–2158, 2011. View at Google Scholar
  44. G. Piaggio, D. R. Elbourne, D. G. Altman, S. J. Pocock, and S. J. W. Evans, “Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement,” Journal of the American Medical Association, vol. 295, no. 10, pp. 1152–1160, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. D. W. Cockcroft and M. H. Gault, “Prediction of creatinine clearance from serum creatinine,” Nephron, vol. 16, no. 1, pp. 31–41, 1976. View at Google Scholar · View at Scopus
  46. J. Stangier, K. Rathgen, H. Sthle, and D. Mazur, “Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study,” Clinical Pharmacokinetics, vol. 49, no. 4, pp. 259–268, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. F. J. A. Penning-Van Beest, E. Van Meegen, F. R. Rosendaal, and B. H. C. Stricker, “Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation,” Thrombosis and Haemostasis, vol. 86, no. 2, pp. 569–574, 2001. View at Google Scholar · View at Scopus
  48. J. G. Gums, “Place of dabigatran in contemporary pharmacotherapy,” Pharmacotherapy, vol. 31, no. 4, pp. 335–337, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. J. L. Mega, E. Braunwald, S. D. Wiviott et al., “Rivaroxaban in patients with a recent acute coronary syndrome,” The New England Journal of Medicine, vol. 366, no. 1, pp. 9–19, 2012. View at Google Scholar
  50. K. Uchino and A. V. Hernandez, “Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials,” Archives of Internal Medicine, vol. 172, no. 5, pp. 397–402, 2012. View at Google Scholar
  51. S. H. Hohnloser, J. Oldgren, S. Yang et al., “Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY trial,” Circulation, vol. 125, no. 5, pp. 669–676, 2012. View at Google Scholar
  52. J. Oldgren, M. Alings, H. Darius et al., “Dabigatran versus warfarin in atrial fibrillation patients with low, moderate and high CHADS2 score: a RE-LY subgroup analysis,” Journal of the American College of Cardiology, vol. 55, no. 10, supplement 1, abstract A1.E2, 2010. View at Google Scholar
  53. M. D. Ezekowitz, L. Wallentin, S. J. Connolly et al., “Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation,” Circulation, vol. 122, no. 22, pp. 2246–2253, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. H. C. Diener, S. J. Connolly, M. D. Ezekowitz et al., “Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial,” The Lancet Neurology, vol. 9, no. 12, pp. 1157–1163, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. L. Wallentin, S. Yusuf, M. D. Ezekowitz et al., “Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial,” The Lancet, vol. 376, no. 9745, pp. 975–983, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. G. J. Hankey, M. R. Patel, S. R. Stevens et al., “Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF,” The Lancet Neurology, vol. 11, no. 4, pp. 315–322, 2012. View at Google Scholar
  57. K. Mahaffey, H. White, C. Nessel, and S. Goodman, “Ischemic cardiac outcomes in patients with AF treated with vitamin K antagonism or Factor Xa inhibition: results from the ROCKET AF trial,” in Proceedings of the AHA/ASA Scientific Sessions, Orlando, Fla, USA, November 2011.
  58. K. A. Fox, J. P. Piccini, D. Wojdyla et al., “Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment,” European Heart Journal, vol. 32, no. 19, pp. 2387–2394, 2011. View at Google Scholar
  59. J. W. Eikelboom, L. Wallentin, S. J. Connolly et al., “Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) Trial,” Circulation, vol. 123, no. 21, pp. 2363–2372, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. J. A. Bovio, S. M. Smith, and J. G. Gums, “Dabigatran etexilate: a novel oral thrombin inhibitor for thromboembolic disease,” Annals of Pharmacotherapy, vol. 45, no. 5, pp. 603–614, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. C. Weinz, U. Buetehorn, H. Daehler et al., “Pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—in rats and dogs,” Pathophysiology of Haemostasis and Thrombosis, vol. 33, supplement 2, Abstract Po054, 2004. View at Google Scholar
  62. L. Wang, K. He, B. Maxwell et al., “Tissue distribution and elimination of [14C]apixaban in rats,” Drug Metabolism and Disposition, vol. 39, no. 2, pp. 256–264, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. M. J. Gnoth, U. Buetehorn, U. Muenster, T. Schwarz, and S. Sandmann, “In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban,” Journal of Pharmacology and Experimental Therapeutics, vol. 338, no. 1, pp. 372–380, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. A. H. Schinkel, “P-Glycoprotein, a gatekeeper in the blood-brain barrier,” Advanced Drug Delivery Reviews, vol. 36, no. 2-3, pp. 179–194, 1999. View at Publisher · View at Google Scholar · View at Scopus
  65. Australian Therapeutic Goods Authority (TGA), “Dabigatran (Pradaxa): risk of bleeding relating to use,” http://www.tga.gov.au/safety/alerts-medicine-dabigatran-111005.htm.
  66. European Medicines Agency, “European Medicines Agency updates on safety of Pradaxa,” http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/11/news_detail_001390.jsp&mid=WC0b01ac058004d5c1&jsenabled=true.
  67. Food and Drug Administration (US FDA), “Drug safety communication—safety review of post-market reports of serious bleeding events,” http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm282820.htm.
  68. European Medicines Agency, “Questions and answers on the review of bleeding risk with Pradaxa (dabigatran etexilate),” http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2012/05/WC500127768.pdf.
  69. B. N. Beasley, E. F. Unger, and R. Temple, “Anticoagulant options—why the FDA approved a higher but not a lower dose of dabigatran,” The New England Journal of Medicine, vol. 364, no. 19, pp. 1788–1790, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. A. S. Go, E. M. Hylek, K. A. Phillips et al., “Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study,” Journal of the American Medical Association, vol. 285, no. 18, pp. 2370–2375, 2001. View at Google Scholar · View at Scopus
  71. A. J. Camm, P. Kirchhof, G. Y. Lip et al., “Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC),” Europace, vol. 12, no. 10, pp. 1360–1420, 2010. View at Google Scholar
  72. V. Fuster, L. E. Rydén, D. S. Cannom et al., “2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,” Circulation, vol. 123, no. 10, pp. e269–e367, 2011. View at Publisher · View at Google Scholar · View at Scopus
  73. M. C. Fang, A. S. Go, Y. Chang, L. Borowsky, N. K. Pomernacki, and D. E. Singer, “Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation,” Journal of the American College of Cardiology, vol. 51, no. 8, pp. 810–815, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. G. Y. H. Lip, R. Nieuwlaat, R. Pisters, D. A. Lane, and H. J. G. M. Crijns, “Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation,” Chest, vol. 137, no. 2, pp. 263–272, 2010. View at Publisher · View at Google Scholar · View at Scopus
  75. J. B. Olesen, G. Y. Lip, M. L. Hansen et al., “Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study,” BMJ, vol. 342, p. d124, 2011. View at Publisher · View at Google Scholar · View at Scopus
  76. R. Pisters, D. A. Lane, R. Nieuwlaat, C. B. De Vos, H. J. G. M. Crijns, and G. Y. H. Lip, “A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey,” Chest, vol. 138, no. 5, pp. 1093–1100, 2010. View at Publisher · View at Google Scholar · View at Scopus
  77. J. A. Cairns, S. Connolly, S. McMurtry, M. Stephenson, and M. Talajic, “Canadian cardiovascular society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter,” Canadian Journal of Cardiology, vol. 27, no. 1, pp. 74–90, 2011. View at Publisher · View at Google Scholar · View at Scopus